CEL-SCI CORP (CVM)

US1508376076 - Common Stock

1.38  +0.02 (+1.47%)

Fundamental Rating

1

Overall CVM gets a fundamental rating of 1 out of 10. We evaluated CVM against 582 industry peers in the Biotechnology industry. CVM may be in some trouble as it scores bad on both profitability and health. CVM does not seem to be growing, but still is valued expensively.



0

1. Profitability

1.1 Basic Checks

CVM had negative earnings in the past year.
In the past year CVM has reported a negative cash flow from operations.
CVM had negative earnings in each of the past 5 years.
CVM had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -99.68%, CVM is not doing good in the industry: 77.64% of the companies in the same industry are doing better.
The Return On Equity of CVM (-209.39%) is worse than 71.40% of its industry peers.
Industry RankSector Rank
ROA -99.68%
ROE -209.39%
ROIC N/A
ROA(3y)-76.3%
ROA(5y)-76.74%
ROE(3y)-142.28%
ROE(5y)-202.3%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CVM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

1

2. Health

2.1 Basic Checks

The number of shares outstanding for CVM has been increased compared to 1 year ago.
CVM has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CVM is higher compared to a year ago.

2.2 Solvency

CVM has an Altman-Z score of -23.61. This is a bad value and indicates that CVM is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -23.61, CVM is not doing good in the industry: 89.60% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.63 indicates that CVM is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.63, CVM is doing worse than 75.22% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF N/A
Altman-Z -23.61
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 1.67 indicates that CVM should not have too much problems paying its short term obligations.
The Current ratio of CVM (1.67) is worse than 80.94% of its industry peers.
CVM has a Quick Ratio of 1.18. This is a normal value and indicates that CVM is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.18, CVM is doing worse than 85.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.67
Quick Ratio 1.18

1

3. Growth

3.1 Past

CVM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.79%, which is quite impressive.
EPS 1Y (TTM)22.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 25.81% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1.84%
EPS Next 2Y14.22%
EPS Next 3Y18.47%
EPS Next 5Y25.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CVM. In the last year negative earnings were reported.
Also next year CVM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CVM's earnings are expected to grow with 18.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.22%
EPS Next 3Y18.47%

0

5. Dividend

5.1 Amount

CVM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CEL-SCI CORP

NYSEARCA:CVM (6/12/2024, 9:14:09 AM)

1.38

+0.02 (+1.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap74.74M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.68%
ROE -209.39%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.67
Quick Ratio 1.18
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)22.79%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-1.84%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y